Evaluation of contemporary treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe – Methodology and rationale for the multinational observational SANTORINI study

Atherosclerosis Plus

Inaam Haq¹  Frank L.J. Visseren²  Ernst Rietzschel³  Aikaterini Bilitou⁴  Carlos Aguiar⁴  Per Hildebrandt⁵  Alberico L. Catapano⁶  Derek L. Connolly⁷  Ulrich Laufs⁸  Timo Strandberg⁹  Marcello Arca^1,10  Kausik K. Ray^1,11  Jean Ferrières^1,12  David Nanchen^1,13  Mats Eriksson^1,14  Jose M. Mostaza^1,15  Hermann Toplak^1,16 

[1] Corresponding author. Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, Level 2, Faculty Building, South Kensington Campus, London, SW7 2AZ, UK.;University of Oulu, Center for Life Course Health Research, Oulu, Finland;Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland;Daiichi Sankyo Europe, Munich, Germany;Department of Cardiology and INSERM UMR 1295, Toulouse Rangueil University Hospital, Toulouse University School of Medicine, Toulouse, France;Department of Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria;Department of Translational and Precision Medicine, Sapienza Università di Roma, Rome, Italy;Frederiksberg Heart Clinic, Frederiksberg, Denmark;Ghent University and Ghent University Hospital, Ghent, Belgium;Heart Institute, Carnaxide, Portugal;Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK;Karolinska University Hospital, Stockholm, Sweden;La Paz-Carlos III Hospital, Madrid, Spain;Sandwell and West Birmingham NHS Trust, Birmingham City Hospital, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK;University Hospital Leipzig, Leipzig, Germany;University of Helsinki and Helsinki University Hospital, Helsinki, Finland;

关键词: Cardiovascular disease;    LDL cholesterol;    High cardiovascular risk;    Lipid-lowering therapy;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background and aims: Clinical practice before 2019 suggests a substantial proportion of high and very high CV risk patients taking lipid-lowering therapy (LLT) would not achieve the new LDL-C goals recommended in the 2019 ESC/EAS guidelines (<70 and < 55 mg/dL, respectively). To what extent practice has changed since the last ESC/EAS guideline update is uncertain, and quantification of remaining implementation gaps may inform health policy. Methods: The SANTORINI study is a multinational, multicentre, prospective, observational, non-interventional study documenting patient data at baseline (enrolment) and at 12-month follow-up. The study recruited 9606 patients ≥18 years of age with high and very high CV risk (as assigned by the investigators) requiring LLT, with no formal patient or comparator groups. The primary objective is to document, in the real-world setting, the effectiveness of current treatment modalities in managing plasma levels of LDL-C in high- and very high-risk patients requiring LLT. Key secondary effectiveness objectives include documenting the relationship between LLT and levels of other plasma lipids, high-sensitivity C-reactive protein (hsCRP) and overall predicted CV risk over one year. Health economics and patient-relevant parameters will also be assessed. Conclusions: The SANTORINI study, which commenced after the 2019 ESC/EAS guidelines were published, is ideally placed to provide important contemporary insights into the evolving management of LLT in Europe and highlight factors contributing to the low levels of LDL-C goal achievement among high and very high CV risk patients. It is hoped the findings will help enhance patient management and reduce the burden of ASCVD in Europe.

【 授权许可】

Unknown